Free tool
FAERS Monitor: Celexa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020822 or its brand name (Celexa, Citalopram Hydrobromide). Reports on generic versions are filed under their own applications.
Reports
114,378
Serious
86,497
76% of reports
Hospitalization
38,084
Death reported
15,414
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue7,613
- nausea7,137
- drug ineffective6,331
- diarrhoea5,443
- headache5,402
- dizziness4,850
- pain4,821
- fall4,768
- anxiety4,682
- dyspnoea4,671
- toxicity to various agents4,505
- off label use4,449
- depression4,396
- vomiting4,280
- malaise3,653
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,488 |
| 2005 | 1,270 |
| 2006 | 1,099 |
| 2007 | 1,009 |
| 2008 | 964 |
| 2009 | 1,680 |
| 2010 | 2,609 |
| 2011 | 3,343 |
| 2012 | 4,660 |
| 2013 | 6,242 |
| 2014 | 7,587 |
| 2015 | 9,711 |
| 2016 | 9,757 |
| 2017 | 8,509 |
| 2018 | 9,026 |
| 2019 | 9,163 |
| 2020 | 7,577 |
| 2021 | 6,260 |
| 2022 | 5,139 |
| 2023 | 5,111 |
| 2024 | 4,489 |
| 2025 | 4,713 |
| 2026 | 2,966 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,939,781 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| toxicity to various agentsSignal | 4,505 | 5.0 | 4.9 | 14,224 |
| depressionSignal | 4,396 | 3.6 | 3.5 | 8,194 |
| anxietySignal | 4,682 | 3.1 | 3.0 | 6,468 |
| fallSignal | 4,768 | 2.7 | 2.6 | 4,938 |
| fatigue | 7,613 | 1.8 | 1.8 | 2,815 |
| dizziness | 4,850 | 1.8 | 1.7 | 1,734 |
| vomiting | 4,280 | 1.7 | 1.6 | 1,194 |
| nausea | 7,137 | 1.7 | 1.6 | 1,948 |
| headache | 5,402 | 1.6 | 1.5 | 1,206 |
| diarrhoea | 5,443 | 1.6 | 1.5 | 1,103 |
| malaise | 3,653 | 1.5 | 1.5 | 692 |
| dyspnoea | 4,671 | 1.5 | 1.5 | 851 |
| pain | 4,821 | 1.4 | 1.4 | 679 |
| off label use | 4,449 | 0.9 | 0.9 | 21 |
| drug ineffective | 6,331 | 0.9 | 0.9 | 104 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.